Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp has demonstrated notable financial performance, with its plasma segment achieving an organic growth rate of 20.2%, highlighting strong demand and market share gains. The company has also improved its adjusted operating margin in the plasma business, which increased by 60 basis points to 36.2%, indicating effective cost management and operational efficiency. Additionally, Haemonetics is projecting an increase in free cash flow expectations, with a revised estimate of $200-220 million, reflecting enhanced financial health and operational strength across its segments.

Haemonetics Corp's financial performance exhibited a significant decline, particularly a 19.6% drop in reported revenue, influenced by divestiture activities, alongside a modest organic growth of only 2.8%. Looking ahead, the company has forecasted a potential revenue decline of 1% to 4% for FY/26, which reflects ongoing challenges, particularly in its interventional technologies segment that saw an alarming 11.6% organic decline. The lack of strong growth metrics in crucial segments such as vascular closure, compounded by the competitive pressures impacting the blood center segment, contributes to a negative outlook on Haemonetics's stock.